Data derived from ReGen Biologics' pivotal meniscus implant trial
was presented last week during the American Academy of Orthopaedic
Surgeons (AAOS) meeting.
The podium presentation, "New Tissue Generated by the Collagen
Meniscus Implant (CMI) Leads to Increased Activity Levels After Two
Years," was given during Specialty Day, a day set aside for programs
produced by the Board of Specialty Societies. It was part of an AOSSM
(American Orthopaedic Society for Sports Medicine) scientific session
focused on the meniscus.
The panel was moderated by Kurt Spindler, M.D. of Nashville and
co-moderated by Benjamin Shaffer, M.D. of Washington, D.C. The CMI
data, authored by William Rodkey, DVM and Karen Briggs, MPh, showed a
significant correlation between change (increase) in Tegner activity
levels over 2 years and percent total meniscus tissue in patients who
receive the CMI implant and have greater than 50% total meniscus
tissue.
The study confirms the importance of preserving as much meniscus
tissue as possible at the time of meniscus treatment, and supports the
potential positive benefits of using the CMI as a scaffold to allow
the patient's own tissue to fill the void left by partial
meniscectomy. A copy of the abstract can be found on the ReGen
Biologics website at http://www.regenbio.com/en/news/default.mspx,
within the AAOS event listing.
With more than 29,000 members, the American Academy of Orthopaedic
Surgeons (www.aaos.org) is the premier not-for-profit organization
that provides education programs for orthopaedic surgeons and allied
health professionals, champions the interests of patients and advances
the highest quality musculoskeletal health. Orthopaedic surgeons and
the Academy are the authoritative sources of information for patients
and the general public on musculoskeletal conditions, treatments and
related issues. This year's meeting had a pre-registration of over
10,400 physicians, including nearly 3000 from outside the United
States.
About ReGen Biologics, Inc.:
ReGen Biologics is a global orthopedic products company that
develops, manufactures and markets innovative tissue growth and repair
products. ReGen's patented collagen scaffold technology includes
applications in orthopedics, general surgery, spine, cardiovascular
and drug delivery. The Company's first approved product using its
collagen scaffold technology is the CMI(TM), a meniscus application
cleared for sale in Europe and marketed through the Company's European
subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the
FDA in the U.S. for clearance of the CMI. ReGen Biologics is
headquartered in Franklin Lakes, NJ and operates a manufacturing plant
in Redwood City, CA. For more information on ReGen, visit
www.regenbio.com.
